Chipscreen Biosciences released its 2026 interim report. First-half net profit attributable to the parent was 71.38 million yuan, up 141.2% year on year. Operating revenue was 543 million yuan, up 33.6% year on year. Net profit attributable to the parent after deducting non-recurring items was 64.7 million yuan, up 218.4% year on year. Net operating cash flow was 89.37 million yuan, up 44.0% year on year. Second-quarter net profit attributable to the parent was 43.11 million yuan, down 11.6% year on year. Sales of the company's core product Chiglitazar Sodium more than doubled, and two solid-dose production lines in Workshop 8 received the drug GMP compliance inspection notification in the second quarter.
Shenzhen Chipscreen Biosciences CoFirst-half net profit up 141.2% and revenue up 33.6%.
